Document is current
Any future updates will be listed below
-
Authors
Appidi, Tejaswini
China, Debarghya
Ștefan, George-Răzvan
Moreau, Michele
Mao, Serena
Velarde, Esteban
Toyang, Ngeh
Lowe, Henry
Rengan, Aravind Kumar
Ding, Kai
Ngwa, Wilfred
-
Funding
Funding for this research was provided by:
National Institutes of Health, United States (R01CA239042, R01CA239042, R01CA239042, R01CA239042, R01CA239042, R01CA239042, R01CA239042, R01CA239042, R01CA239042, R01CA239042, R01CA239042)
- License Information
-
More Information
Article History
Received: 2 January 2025
Accepted: 7 February 2025
First Online: 6 March 2025
Declarations
:
: All animal experiments were approved by the Animal Care and Use Committee of the Johns Hopkins University Animal Care and Use Committee (ACUC) for protocol #MO21M281, approved on 6 October 2021.
: All authors have consented to submit this article for publication.
: The authors NT and HL are employees of Flavocure Biotech Inc., which has commercial interest in developing Caflanone. All the other authors declare no competing interests.
